Skip to main content

Debendox

Volume 977: debated on Thursday 31 January 1980

The text on this page has been created from Hansard archive content, it may contain typographical errors.

asked the Secretary of State for Social Services, pursuant to his reply of 24 January to the right hon. Member for Stoke-on-Trent, South, if, when the Committee on the Safety of Medicines considered the possible teratogenic effects to antihistamines in June 1978 and February 1979, it had held a specific and separate inquiry into the drug Debendox;

  • (2) pursuant to his reply of 24 January to the right hon. Member for Stoke-on Trent, South, which particular reports he was referring to concerning cases of congenital abnormalities occurring in the children of women taking antihistamines such as Debendox;
  • (3) pursuant to his reply of 24 January to the right hon. Member for Stoke-on-Trent, South, if following the granting of a product licence of right to Debendox in 1972, the same rigorous testing of this drug has been undertaken similar to that of new drugs;
  • (4) if he will make a statement giving his estimate of the safety of the drug Debendox;
  • (5) pursuant to his reply of 24 January to the right hon. Member for Stoke-on-Trent, South, if he will specify what research he was referring to which had not established any causal relationship between Debendox and congenital abnormalities; if special research has been conducted by the Committee on the Safety of Medicines; and if he considers that no further research is now necessary.